Edward Md Kaye Sells 12,567 Shares of Stoke Therapeutics (NASDAQ:STOK) Stock

Posted by Brian Himes on Aug 18th, 2026

Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Free Report) Director Edward Md Kaye sold 12,567 shares of Stoke Therapeutics stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $32.03, for a total value of $402,521.01. Following the transaction, the director directly owned 124,557 shares of the company’s stock, valued at approximately $3,989,560.71. This represents a 9.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Stoke Therapeutics Trading Up 0.0%

Shares of NASDAQ:STOK traded up $0.01 during midday trading on Tuesday, hitting $32.14. 574,554 shares of the stock were exchanged, compared to its average volume of 816,472. The stock has a market cap of $2.07 billion, a P/E ratio of -9.62 and a beta of 1.20. Stoke Therapeutics, Inc. has a twelve month low of $18.00 and a twelve month high of $40.22. The company has a 50 day moving average price of $30.81 and a 200-day moving average price of $32.21.

Stoke Therapeutics (NASDAQ:STOK – Get Free Report) last announced its earnings results on Monday, August 3rd. The company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.13). The business had revenue of $9.32 million for the quarter, compared to analyst estimates of $4.89 million. Stoke Therapeutics had a negative return on equity of 59.36% and a negative net margin of 753.60%. On average, equities research analysts expect that Stoke Therapeutics, Inc. will post -3.5 earnings per share for the current year.

Wall Street Analyst Weigh In

STOK has been the subject of a number of research analyst reports. Wedbush upped their price objective on shares of Stoke Therapeutics from $38.00 to $40.00 and gave the company an “outperform” rating in a research note on Tuesday, August 4th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Stoke Therapeutics in a research report on Friday, August 7th. Guggenheim reissued a “buy” rating and set a $60.00 target price on shares of Stoke Therapeutics in a research report on Tuesday, August 4th. BTIG Research restated a “buy” rating and issued a $39.00 target price on shares of Stoke Therapeutics in a research note on Monday, May 11th. Finally, The Goldman Sachs Group started coverage on shares of Stoke Therapeutics in a report on Monday, July 13th. They set a “buy” rating and a $44.00 price target for the company. Nine analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $43.00.

Check Out Our Latest Stock Report on STOK

Hedge Funds Weigh In On Stoke Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in STOK. Kestra Advisory Services LLC bought a new stake in shares of Stoke Therapeutics in the fourth quarter worth $26,000. Quantbot Technologies LP bought a new stake in shares of Stoke Therapeutics in the 2nd quarter worth about $34,000. KBC Group NV bought a new position in shares of Stoke Therapeutics during the first quarter worth about $36,000. Harbour Investments Inc. grew its position in shares of Stoke Therapeutics by 312.9% in the 4th quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock worth $38,000 after acquiring an additional 898 shares in the last quarter. Finally, BNP Paribas Financial Markets boosted its holdings in Stoke Therapeutics by 66.2% in the second quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock worth $48,000 after purchasing an additional 1,668 shares during the period.

Stoke Therapeutics Company Profile

(Get Free Report)

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.